头孢哌酮舒巴坦治疗肺癌并发阻塞性肺炎30例

Observation of Clinical Effects of Cefoperazone/Sulbactam in the Treatment of Pulmonary Carcinoma Complicated with Obstructive Pneumonia

目的:研究头孢哌酮舒巴坦(cefoperozone and sulbactam,CPZ/SBT)qd 给药方案,治疗肺癌并发阻塞性肺炎的临床疗效,并以血清杀菌活性(Serum Bactericidal Activity,SBA)为指标进行实验室评价。方法:30例肺癌并发阻塞性肺炎患者,给予 CPZ/SBT4.0 g,ivd qd,持续7 d。测定峰时及谷时 SBA。结果:临床有效率86.7%,细菌清除率90.9%。血清杀菌活性峰值中位数均≥1:16,SBA≥1:8百分率均≥70%。结论:CPZ/SBT 日剂量4.0 g,ivd qd,治疗肺癌并发阻塞性肺炎患者疗效满意。

Objective： To explore the clinical effects and serum bactericidal activities （SBA） of once -daily （qd） administration of cefoperazone/sulbactam （CPZ/SBT）. Method： 30 patients suffering from pulmonary carcinoma complicated with obstructive pneumonia were given CPZ/SBT 4g, qd ivd for a course of 7 days to determine their peak and trough SBAs of CPZ/SBT against 5 species organisms （22 strains, each ） respectively. Result： The medians of the peak SBAs were all ≥ 1：16, the percentage of peak SBA 1≥1：8 was≥70% , the effective rate was 86.7% , and the germ clearance rate was 90.9%. Conclusion： It is suggested that the once-daily administration of CPZ/SBT is an appropriate therapy for patients suffering from pulmonary carcinoma complicated with obstructive pneumonia.